Moderna, Inc. Other Noncash Income (Expense)
Moderna, Inc. (MRNA) reported Other Noncash Income (Expense) of -$10.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-07-31
- Moderna, Inc. other noncash income (expense) for the quarter ending 2026-06-30 was -$4.00M.
- Moderna, Inc. other noncash income (expense) for the quarter ending 2026-03-31 was -$6.00M.
- Moderna, Inc. other noncash income (expense) for the quarter ending 2025-12-31 was -$27.00M.
- Moderna, Inc. other noncash income (expense) for the quarter ending 2025-09-30 was -$14.00M, a 1500.00% decline year-over-year.
- Moderna, Inc. other noncash income (expense) for fiscal 2025 was -$77.00M.
- Moderna, Inc. other noncash income (expense) for fiscal 2024 was -$60.00M.
- Moderna, Inc. other noncash income (expense) for fiscal 2023 was -$7.00M.
- Moderna, Inc. other noncash income (expense) for fiscal 2022 was -$28.00M.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$10.00M 10-Q · filed 2026-07-31 | -$37.00M derived: sum of 3 quarters · filed 2026-07-31 | -$51.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | -$6.00M 10-Q · filed 2026-05-01 | -$33.00M derived: sum of 2 quarters · filed 2026-05-01 | -$47.00M derived: sum of 3 quarters · filed 2026-05-01 | -$81.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | -$27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$41.00M derived: sum of 2 quarters · filed 2026-02-20 | -$75.00M derived: sum of 3 quarters · filed 2026-07-31 | -$77.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | -$14.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$48.00M derived: sum of 2 quarters · filed 2026-07-31 | -$50.00M 10-Q · filed 2025-11-06 | -$104.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | -$34.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$36.00M 10-Q · filed 2026-07-31 | -$90.00M derived: sum of 3 quarters · filed 2026-07-31 | -$89.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | -$2.00M 10-Q · filed 2026-05-01 | -$56.00M derived: sum of 2 quarters · filed 2026-05-01 | -$55.00M derived: sum of 3 quarters · filed 2026-05-01 | -$59.00M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | -$54.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$53.00M derived: sum of 2 quarters · filed 2026-02-20 | -$57.00M derived: sum of 3 quarters · filed 2026-02-20 | -$60.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.00M derived: sum of 2 quarters · filed 2025-11-06 | -$6.00M 10-Q · filed 2025-11-06 | $12.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | -$4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | -$7.00M 10-Q · filed 2025-08-01 | $11.00M derived: sum of 3 quarters · filed 2026-02-20 | -$26.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | -$3.00M 10-Q · filed 2025-05-01 | $15.00M derived: sum of 2 quarters · filed 2026-02-20 | -$22.00M derived: sum of 3 quarters · filed 2026-02-20 | -$14.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$19.00M derived: sum of 2 quarters · filed 2026-02-20 | -$11.00M derived: sum of 3 quarters · filed 2026-02-20 | -$7.00M 10-K · filed 2026-02-20 |
| 2023-09-30 | -$37.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$29.00M derived: sum of 2 quarters · filed 2024-11-07 | -$25.00M 10-Q · filed 2024-11-07 | -$17.00M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $12.00M 10-Q · filed 2024-08-01 | $20.00M derived: sum of 3 quarters · filed 2025-02-21 | -$1.00M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $4.00M 10-Q · filed 2024-05-02 | $12.00M derived: sum of 2 quarters · filed 2025-02-21 | -$9.00M derived: sum of 3 quarters · filed 2025-02-21 | -$24.00M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$13.00M derived: sum of 2 quarters · filed 2025-02-21 | -$28.00M derived: sum of 3 quarters · filed 2025-02-21 | -$28.00M 10-K · filed 2025-02-21 |
| 2022-09-30 | -$21.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$36.00M derived: sum of 2 quarters · filed 2023-11-03 | -$36.00M 10-Q · filed 2023-11-03 | -$36.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | -$15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$15.00M 10-Q · filed 2023-08-03 | -$15.00M derived: sum of 3 quarters · filed 2024-02-23 | -$15.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2024-02-23 | $0.00 derived: sum of 3 quarters · filed 2024-02-23 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $0.00 derived: sum of 2 quarters · filed 2024-02-23 | $0.00 10-K · filed 2024-02-23 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-03 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |